• Explore /
  • Poster
  • / Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

Abstract Poster

Authors

null

Kay T Yeung

University of California, San Diego, La Jolla, CA

Kay T Yeung , Kevin Kalinsky , Christina Yau , Amy Jo Chien , Judy Caroline Boughey , Erica Michelle Stringer-Reasor , Carla Isadora Falkson , Kathy S. Albain , Ingrid A. Mayer , Meghna S. Trivedi , Rita Nanda , Emily H. Douglas , Coral Oghenerukevwe Omene , Hope S. Rugo , Claudine Isaacs , Beverly Parker , Angela DeMichele , Douglas Yee , Laura Esserman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT01042379

Citation

J Clin Oncol 41, 2023 (suppl 17; abstr LBA520)

DOI

10.1200/JCO.2023.41.17_suppl.LBA520

Abstract #

LBA520

Poster Bd #

350

Abstract Disclosures

Similar Posters

First Author: Rebecca Arielle Shatsky

First Author: M. Luque

First Author: Philip C. Schouten

First Author: Zefei Jiang